- Home
- CRMD vs BCAX Comparison
CRMD vs BCAX Comparison
Compare CRMD & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- BCAX
- Stock Information
- Founded
- CRMD 2006
- BCAX 2018
- Country
- CRMD United States
- BCAX United States
- Employees
- CRMD N/A
- BCAX N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- BCAX
- Sector
- CRMD Health Care
- BCAX
- Exchange
- CRMD Nasdaq
- BCAX NYSE
- Market Cap
- CRMD 645.0M
- BCAX 670.9M
- IPO Year
- CRMD 2010
- BCAX 2024
- Fundamental
- Price
- CRMD $6.06
- BCAX $12.80
- Analyst Decision
- CRMD Strong Buy
- BCAX Strong Buy
- Analyst Count
- CRMD 7
- BCAX 6
- Target Price
- CRMD $15.14
- BCAX $34.20
- AVG Volume (30 Days)
- CRMD 2.0M
- BCAX 603.5K
- Earning Date
- CRMD 03-25-2025
- BCAX 03-27-2025
- Dividend Yield
- CRMD N/A
- BCAX N/A
- EPS Growth
- CRMD N/A
- BCAX N/A
- EPS
- CRMD N/A
- BCAX N/A
- Revenue
- CRMD $43,472,170.00
- BCAX N/A
- Revenue This Year
- CRMD $204.98
- BCAX N/A
- Revenue Next Year
- CRMD $22.54
- BCAX N/A
- P/E Ratio
- CRMD N/A
- BCAX N/A
- Revenue Growth
- CRMD N/A
- BCAX N/A
- 52 Week Low
- CRMD $3.61
- BCAX $11.10
- 52 Week High
- CRMD $13.85
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- CRMD 22.86
- BCAX N/A
- Support Level
- CRMD $6.92
- BCAX N/A
- Resistance Level
- CRMD $11.32
- BCAX N/A
- Average True Range (ATR)
- CRMD 0.65
- BCAX 0.00
- MACD
- CRMD -0.48
- BCAX 0.00
- Stochastic Oscillator
- CRMD 2.27
- BCAX 0.00
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.